↓ Skip to main content

Dove Medical Press

Article Metrics

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab

Overview of attention for article published in Drug Design, Development and Therapy, December 2014
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
37 Mendeley
Title
Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
Published in
Drug Design, Development and Therapy, December 2014
DOI 10.2147/dddt.s50348
Pubmed ID
Authors

Daniel Baumgart, Niklas Krupka

Abstract

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. Here we discuss the clinical trial results of vedolizumab (anti-α4β7, LDP-02, MLN-02, and MLN0002) and its impact on future management of inflammatory bowel disease.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 37 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 16%
Researcher 5 14%
Other 5 14%
Student > Doctoral Student 4 11%
Student > Bachelor 4 11%
Other 8 22%
Unknown 5 14%
Readers by discipline Count As %
Medicine and Dentistry 19 51%
Agricultural and Biological Sciences 3 8%
Immunology and Microbiology 2 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Computer Science 1 3%
Other 4 11%
Unknown 6 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2015.
All research outputs
#10,012,017
of 12,510,237 outputs
Outputs from Drug Design, Development and Therapy
#765
of 1,315 outputs
Outputs of similar age
#190,882
of 282,706 outputs
Outputs of similar age from Drug Design, Development and Therapy
#26
of 41 outputs
Altmetric has tracked 12,510,237 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,315 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,706 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.